Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 Pandemic

Article

Stephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.

Stephen Schuster, MD, of Penn Medicine talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.

Transcription:

As I said, some of our visits that are very routine can be done remotely. That actually saves time, number 1, and it also reduces traffic to the cancer center and through the waiting room and into the exam room. I think if we can continue to maintain that, we’ll have greater capacity to see patients that need to be seen. People that are being evaluated up front with either a new diagnosis or for evaluation for CAR T, we’ll be able to bring more patients in because our schedule won’t be quite as cluttered with routine follows up, which we can still do, but we can do more efficiently and remotely. We’ll have more space in clinic, more space in our schedules, and probably be able to handle a greater volume of patients.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content